Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease.
Bo-Ryoung ChoiWoo-Hyun ChoJiyoung KimHyong Joo LeeChiHye ChungWon Kyung JeonJung-Soo HanPublished in: Experimental & molecular medicine (2014)
The receptor for advanced glycation end products (RAGE) has been reported to have a pivotal role in the pathogenesis of Alzheimer's disease (AD). This study investigated RAGE levels in the hippocampus and cortex of a triple transgenic mouse model of AD (3xTg-AD) using western blotting and immunohistochemical double-labeling to assess cellular localization. Analysis of western blots showed that there were no differences in the hippocampal and cortical RAGE levels in 10-month-old adult 3xTg-AD mice, but significant increases in RAGE expression were found in the 22- to 24-month-old aged 3xTg-AD mice compared with those of age-matched controls. RAGE-positive immunoreactivity was observed primarily in neurons of aged 3xTg-AD mice with very little labeling in non-neuronal cells, with the notable exception of RAGE presence in astrocytes in the hippocampal area CA1. In addition, RAGE signals were co-localized with the intracellular amyloid precursor protein (APP)/amyloid beta (Aβ) but not with the extracellular APP/Aβ. In aged 3xTg-AD mice, expression of human tau was observed in the hippocampal area CA1 and co-localized with RAGE signals. The increased presence of RAGE in the 3xTg-AD animal model showing critical aspects of AD neuropathology indicates that RAGE may contribute to cellular dysfunction in the AD brain.
Keyphrases
- mouse model
- poor prognosis
- cerebral ischemia
- oxidative stress
- spinal cord
- cognitive decline
- south africa
- young adults
- type diabetes
- mass spectrometry
- cell death
- multiple sclerosis
- brain injury
- mild cognitive impairment
- cell cycle arrest
- insulin resistance
- white matter
- signaling pathway
- blood brain barrier
- wild type
- atomic force microscopy